6-(2,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one | 401632-75-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-(2,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one
• 英文别名: 3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyridazin-6-one
• CAS: 401632-75-5
• 化学式: C₁₂H₁₄N₂O₃
• 分子量: 234.255
• InChiKey: ATEGSTMVOCPNOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  59.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(2,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one 在 三溴化硼 、 potassium carbonate 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 生成
  参考文献：
  名称：

  Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity

  摘要：

  H3R structure-activity relationships on a novel class of pyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modifications of the pyridazinone core, central phenyl ring and linker led to the identification of molecules with excellent target potency, selectivity and pharmacokinetic properties. Compounds 13 and 21 displayed potent functional H3R antagonism in vivo in the rat dipsogenia model and demonstrated robust wake activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.108

文献信息

• [DE] PYRIDAZINONE ALS ENDOTHELIN-REZEPTOR-ANTAGONISTEN<br/>[EN] PYRIDAZINONES AS ENDOTHELIN-RECEPTOR ANTAGONISTS<br/>[FR] PYRIDAZINONES UTILES COMME ANTAGONISTES DU RECEPTEUR DE L'ENDOTHELINE
  申请人：MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG

  公开号：WO1997013758A1

  公开（公告）日：1997-04-17

  (DE) Neue Verbindungen der Formel (I), worin R1, R2, R3 und Y die in Patentanspruch 1 angegebene Bedeutung haben, sowie deren Salze zeigen Endothelinrezeptor-antagonistische Eigenschaften.(EN) Novel compounds of formula (I), wherein R1, R2, R3 and Y have the meanings indicated in claim 1, and their salts, have endothelin-receptor antagonistic properties.(FR) L'invention concerne de nouveaux composés de la formule (I) où R1, R2, R3 et Y ont la signification donnée dans la revendication 1. L'invention concerne également leurs sels. Lesdits nouveaux composés ont des propriétés antagonistes du récepteur de l'endothéline.

  新连接的类型(I)，其中R1、R2、R3和Y代表专利要求1中指示的意义，以及它们的盐，显示出内皮细胞非角化素受体拮抗作用特性。
• Pyridazinones with a pendant acylsulfonamide moiety as endothelin receptor antagonists
  作者：Dieter Dorsch、Werner W.K.R. Mederski、Mathias Osswald、Ralf M. Devant、Claus-Jochen Schmitges、Maria Christadler、Claudia Wilm

  DOI：10.1016/s0960-894x(96)00617-8

  日期：1997.2

  Highly active endothelin receptor antagonists can be obtained by replacing the aryloxy group of L-749,329 by diversely substituted pyridazinone residues. The syntheses and structure-activity relationships of the new aryl-oxopyridazinyl-N-(4-arylsulfonyl)-acetamides 2 are reported. 2p with a simple dimethylpyridazinone moiety was one of the most potent compounds in vitro. (C) 1997, Elsevier Science Ltd.
• PYRIDAZINONE ALS ENDOTHELIN-REZEPTOR-ANTAGONISTEN
  申请人：MERCK PATENT GmbH

  公开号：EP0796250A1

  公开（公告）日：1997-09-24
• US5883090A
  申请人：——

  公开号：US5883090A

  公开（公告）日：1999-03-16
• Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity
  作者：Robert L. Hudkins、Lisa D. Aimone、Thomas R. Bailey、Robert J. Bendesky、Reddeppa reddy Dandu、Derek Dunn、John A. Gruner、Kurt A. Josef、Yin-Guo Lin、Jacquelyn Lyons、Val R. Marcy、Joanne R. Mathiasen、Babu G. Sundar、Ming Tao、Allison L. Zulli、Rita Raddatz、Edward R. Bacon

  DOI：10.1016/j.bmcl.2011.06.108

  日期：2011.9

  H3R structure-activity relationships on a novel class of pyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modifications of the pyridazinone core, central phenyl ring and linker led to the identification of molecules with excellent target potency, selectivity and pharmacokinetic properties. Compounds 13 and 21 displayed potent functional H3R antagonism in vivo in the rat dipsogenia model and demonstrated robust wake activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.